Markets
PLX

Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%

Protalix BioTherapeutics, Inc.PLX was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 63% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Friday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Protalix BioTherapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

Protalix BioTherapeutics, Inc. Price

Protalix BioTherapeutics, Inc. Price | Protalix BioTherapeutics, Inc. Quote

A better-ranked stock in the same industry is Sunesis Pharmaceuticals, Inc. SNSS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is PLX going up? Or down? Predict to see what others think: Up or Down

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Protalix BioTherapeutics, Inc. (PLX): Free Stock Analysis Report

Sunesis Pharmaceuticals, Inc. (SNSS): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PLX SNSS

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More